$ELTX News

Elicio Therapeutics Announces Publication Of Peer-Reviewed Manuscript In Science Advances Describing Novel AMP-DNA Adjuvant Candidates

HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $17 Price Target

Elicio Therapeutics (NASDAQ:ELTX) Q1 2026 Results Show Extended Cash Runway Ahead of Key Phase 2 Data Readout

Elicio Therapeutics Q1 EPS $(0.65) Misses $(0.47) Estimate

Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out

Ladenburg Thalmann Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $20

Elicio Therapeutics Launches $100M At-The-Market Offering Program, Replaces Prior $40M Sales Agreement

Elicio Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results. Also, HC Wainwright & Co raised its price target from $13 to $17.

Elicio Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results. Also, HC Wainwright & Co raised its price target from $13 to $17.

HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $17

Elicio Therapeutics Q4 EPS $(0.45) Beats $(0.47) Estimate

Elicio Therapeutics shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $17 price target.

Rodman & Renshaw Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $17

Elicio Therapeutics Files Preliminary Prospectus To Issue Up To $400M In Securities

While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Elicio Therapeutics Announces That Analysis Of Subset Of Patients In Ongoing Phase 2 AMPLIFY-7P Trial Shows That Majority Of Evaluated Patients Treated With ELI-002 7P Induced Antigen Spreading Targeting Non-mKRAS Neoantigens That Are Not Present In ELI-002 7P Targeted Immunotherapy